Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

January 2026 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

January 16, 2026

Coverage and Use of Impella and Watchman: A Tale of Four Countries

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

October 02, 2024

June 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

June 01, 2024

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

FDA Approves Colchicine for Decreasing CV Events

News Daily News

FDA Approves Colchicine for Decreasing CV Events

June 20, 2023

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

News Daily News

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

March 25, 2021

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

June 01, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.